|
POU5F1P4
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In agreement, we find that FUT9 silencing decreases the expression of the colorectal cancer TIC marker CD44 and the level of the OCT4 transcription factor, which is known to support cancer stemness.
|
29196508 |
2017 |
|
POU5F1P4
|
0.100 |
AlteredExpression
|
group |
BEFREE |
DU145R80 show a cancer stem cell (CSC)-like signature with a high expression of CSC markers including CD44, CD133, NANOG, Snail, Oct4 and ALDH7A1 and CSC-related genes as STAT3.
|
26312765 |
2015 |
|
POU5F1P4
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, during ethanol-induced cellular transformation, cells gained the phenotypes of cancer stem cells (CSCs) by expressing pluripotency maintaining factors (Oct4, Sox2, cMyc and KLF4) and stem cell markers (CD24, CD44 and CD133).
|
29761897 |
2018 |
|
POU5F1P4
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although differentially displayed, the expression of genes related to cancer (BCL-2, p53, NF-κB, TGF-β, VEGF) and transcription and pluripotency (OCT4, NANOG, STAT3, REX1) were commonly observed in MSCs and cancer cells.
|
21638208 |
2011 |
|
POU5F1P4
|
0.100 |
Biomarker
|
group |
BEFREE |
A similar treatment also modulated numerous microRNAs (miRs) including one regulator of Oct4 as well as miRs involved in oncogenesis and/or malignancy, with only a few estrogen-induced miRs.
|
27959387 |
2017 |
|
POU5F1P4
|
0.100 |
Biomarker
|
group |
BEFREE |
Oct4, a member of the POU-domain transcription factor family, has been implicated in the cancer stem cell (CSC)-like properties of various cancers.
|
22037460 |
2011 |
|
POU5F1P4
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In order to investigate the potential of Sox2-Oct4 transcription factor decoy (TFD) strategy for differentiation therapy, mouse embryonic stem cells (mESCs) were used in this study as a model of cancer stem cells (CSCs).
|
28833847 |
2017 |
|
POU5F1P4
|
0.100 |
Biomarker
|
group |
BEFREE |
Since cancer stem cells (CSCs) are radioresistant and metastasis-initiating cells, we examined TGLI1 for its involvement in breast CSCs and found TGLI1 to transcriptionally activate stemness genes CD44, Nanog, Sox2, and OCT4 leading to CSC renewal, and TGLI1 outcompetes with GLI1 for binding to target promoters.
|
31462709 |
2020 |
|
POU5F1P4
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In CSE-transformed HBE cells, the protein level of Oct-4 and mRNA levels of CD133 and CD44, indicators of the acquisition of CSC-like properties, were reduced by over-expression of miR-218, and over-expression of miR-218 decreased the malignancy of transformed HBE cells.
|
25526925 |
2016 |
|
POU5F1P4
|
0.100 |
Biomarker
|
group |
BEFREE |
To investigate whether Oct4, Sox2 and Nanog, three core regulatory factors maintaining pluripotency and self-renewal of embryonic stem cells (ESCs), are coexpressed in human gliomas, and whether their expression might be linked to carcinogenesis and the formation of cancer stem cells (CSCs).
|
22014056 |
2011 |
|
POU5F1P4
|
0.100 |
Biomarker
|
group |
BEFREE |
Octamer-binding transcription factor 4 (OCT4) has been implicated in cancer metastasis.
|
23076549 |
2013 |
|
POU5F1P4
|
0.100 |
Biomarker
|
group |
BEFREE |
Nuclear localization signal-enhanced RNA interference of EZH2 and Oct4 in the eradication of head and neck squamous cell carcinoma-derived cancer stem cells.
|
22361100 |
2012 |
|
POU5F1P4
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.
|
22847005 |
2012 |
|
POU5F1P4
|
0.100 |
Biomarker
|
group |
BEFREE |
Global Oct4 target gene analysis reveals novel downstream PTEN and TNC genes required for drug-resistance and metastasis in lung cancer.
|
25609695 |
2015 |
|
POU5F1P4
|
0.100 |
Biomarker
|
group |
BEFREE |
The implications are either in vivo existence of Oct4 positive putative cancer stem cells in ESCC or acquisition of cancer stem cell properties by tumor cells as a response to treatment given, resulting ultimately an uncontrolled cell proliferation and treatment failure.
|
24870750 |
2014 |
|
POU5F1P4
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of Cancer Stem Cell Markers OCT4 and CD133 in Transitional Cell Carcinomas.
|
26945449 |
2017 |
|
POU5F1P4
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Oct4 is expressed by CSC-like cells in different types of cancer.
|
22286766 |
2012 |
|
POU5F1P4
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, TGFβ1 was able to enhance the mRNA expression of Oct4, Nanog and Sox2 and drastically increased anchorage-independent colony formation in TGFβ1-sensitive NSCLC cells, suggesting the acquisition of cancer stem-like properties.
|
29995950 |
2018 |
|
POU5F1P4
|
0.100 |
Biomarker
|
group |
BEFREE |
The results demonstrated Wnt/β-catenin signaling was activated and was able to form mammospheres with increased cancer stem cell markers (ALDH1, NANOG, and OCT4) in endocrine-resistant cells.
|
31693936 |
2019 |
|
POU5F1P4
|
0.100 |
Biomarker
|
group |
BEFREE |
A strategy to target "cancer stem cells" is to suppress the Oct-4 gene in order to cause the cells to differentiate.
|
17261754 |
2006 |
|
POU5F1P4
|
0.100 |
Biomarker
|
group |
BEFREE |
More importantly, the expression levels of epithelial-mesenchymal transition biomarkers (N-cadherin and vimentin) and cell stemness biomarkers (nanog, sox2, and oct3/4) considerably increased in HepG2 with dopamine-induced SULT1A3/4, whereas in L02, epithelial-mesenchymal transition and cancer stem cell-associated proteins were contrarily decreased.
|
29025375 |
2017 |
|
POU5F1P4
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, treatment of HB cells with aprepitant led to reduced expression of (liver) stemness markers (AFP, CD13, SOX2, NANOG, and OCT4) and SFA when grown under cancer stem cell conditions.
|
26516161 |
2015 |
|
POU5F1P4
|
0.100 |
Biomarker
|
group |
BEFREE |
This hypothesis is further supported by the recent understanding that: i) cancer is a stem cell disease and OSE is the niche for ovarian cancer stem cells; ii) ovarian OCT4-positive stem cells are regulated by FSH; and iii) OCT4 along with LIN28 and BMP4 are highly expressed in ovarian cancers.
|
25269615 |
2015 |
|
POU5F1P4
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Analysis of SOX2, OCT4 and MSI1 expression revealed that inhibition of the dominant p110 subunit increased expression of cancer stem cell genes, while pan-PI3K/mTOR inhibition caused a similar, though not identical, increase in cancer stem cell gene expression.
|
27176780 |
2016 |
|
POU5F1P4
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<i>NANOG</i> and <i>OCT3/4</i> mRNA expression levels were significantly downregulated while that of <i>SOX2</i> was upregulated in cancer compared to noncancer tissues.
|
29849920 |
2018 |